Skip to content
Sunday 16 August 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE
MorningWire

European business, markets and politics

FTSE 100
10,750.11
-0.21%
DAX
26,440.31
+0.53%
CAC 40
8,636.80
-0.16%
STOXX 50
6,539.59
-0.09%
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
More
GermanyFranceBankingAIEnergyFintechPropertyCapital Markets
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
  • DE
Tuesday 08 August 2023 3:26 pm  |  Updated:  Tuesday 08 August 2023 4:40 pm

Tribunal upholds £84m CMA fine for firm that hiked drug prices

By: Morning Wire Reporter

Add as a preferred source on Google

The companies behind a drug whose price was hiked from £20 to £248 per pack in just eight years will be fined a combined £84 million after a tribunal upheld the competition watchdog’s decision.

The Competition Appeal Tribunal on Tuesday had endorsed “all the main elements” of the Competition and Markets Authority’s decision, the CMA said.

However it reduced the overall fine for the three businesses from around £101 million.

The CMA said that the price of a packet of liothyronine tablets had increased by more than 12-fold between 2009 and 2017.

The only supplier of the tablets, used to treat thyroid hormone deficiency, was Advanz.

Advanz is currently owned by Advanz Pharma, but previous owners Cinven and HgCapital also share in the fine.

Advanz Pharma will pay £40.9 million, Cinven £37.1 million and Hg £6.2 million, the tribunal decided.

Cinven declined to comment, Advanz Pharma and Hg have been contacted.

CMA executive director of enforcement Michael Grenfell said: “We are delighted that the Competition Appeal Tribunal has unanimously upheld the CMA’s infringement findings.

Read more

Competition watchdog clears Paramount Warner Bros acquisition

Paramount, Netflix, Warner logos; media giants intensifying streaming competition and strategic industry shifts

“Today’s landmark judgment reinforces the need for companies to think carefully about how they set prices and paves the way for the NHS to seek compensation.

“The CMA will continue to crack down on companies which abuse their market power in ways that harm people and the wider economy.”

The CMA said that its finding that Advanz abused its dominant position had been upheld by the tribunal.

It had charged “excessive and unfair prices,” the CMA said.

“In particular, the Tribunal found that the price increases were part of a deliberate strategy to exploit the lack of regulatory or competitive constraints and resulted in a significant impact on the NHS.

“The Tribunal dismissed all of the appellants’ grounds of appeal on liability.

“NHS annual spending on the tablets in 2006, the year before the implementation of the strategy, was £600,000, but by 2009 had increased to more than £2.3 million and jumped to more than £30 million by 2016.”

Press Association –  August Graham

Read more

Sky and ITV mount defence of £1.6bn merger as regulators probe deal

Turnover at Sky increased in 2024.

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • News

Categories

  • Tech

Related Topics

  • Competition and Markets Authority
  • NHS
  • Pharmaceuticals
  • Pharmaceuticals

Trending Articles

  • Grandparents fund university degrees to avoid inheritance tax net

  • Revolut chatbot goes rogue by charging users to cancel subscription

  • Brompton Bicycle sues former adviser for ‘professional negligence’

  • Revolut takes flight with launch of new airport lounges

  • Is the Zeekr 9X Super Hybrid the new luxury SUV to beat?

More from Morning Wire

  • Competition watchdog clears Paramount Warner Bros acquisition

    Media
    Paramount, Netflix, Warner logos; media giants intensifying streaming competition and strategic industry shifts
  • Sky and ITV mount defence of £1.6bn merger as regulators probe deal

    Media
    Turnover at Sky increased in 2024.
  • Retailers hit back at Healey’s ‘profiteering’ threat

    Retail
    Chancellor John Healey smiling, wearing a navy suit, white shirt, and red tie.
  • Could a ‘land blocking’ rule change spell danger for Aldi and Lidl?

    Retail
    Lidl supermarket sign with blue, yellow, and red logo against a clear blue sky
  • ITV hands shareholders £100m returns after £1.6bn Sky deal

    Media
    Studios revenue rose three per cent to £893m, driven by an 11 per cent jump in external sales to streaming platforms.
  • TikTok loses court battle over £12.7m child privacy fine

    Tech
    Tiktok appeals to overturn US ban in a broader battle for tech regulation
  • ITV says ‘no guarantees’ on jobs after £1.6bn Sky deal

    Media
    Studios revenue rose three per cent to £893m, driven by an 11 per cent jump in external sales to streaming platforms.
  • Cycle Pharmaceuticals Selects Forma Life Sciences to Establish U.S. Commercial Supply for FDA-Approved CAVHANZA™ (nilotinib) Orally Disintegrating Tablets

    Business Wire
MorningWire

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • Europe
  • UK & Ireland

Business

  • Markets
  • Banking
  • Technology
  • Energy
  • Property
  • Fintech

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About Morning Wire
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 Morning Wire Ltd · Published by Morning Wire Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook